Aligos Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aligos Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2024.
  • Aligos Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 77.1 %, a 63.8% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 77.1 +30 +63.8% Sep 30, 2024
Q2 2024 73.1 +31.4 +75.5% Jun 30, 2024
Q1 2024 70.6 +33.2 +88.8% Mar 31, 2024
Q4 2023 54.4 +18 +49.3% Dec 31, 2023
Q3 2023 47.1 +14.2 +43.3% Sep 30, 2023
Q2 2023 41.6 +12.7 +44.1% Jun 30, 2023
Q1 2023 37.4 +10.1 +37.2% Mar 31, 2023
Q4 2022 36.4 +13.1 +55.9% Dec 31, 2022
Q3 2022 32.8 +11.2 +51.4% Sep 30, 2022
Q2 2022 28.9 -9.96 -25.6% Jun 30, 2022
Q1 2022 27.3 Mar 31, 2022
Q4 2021 23.4 Dec 31, 2021
Q3 2021 21.7 Sep 30, 2021
Q2 2021 38.9 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.